Category Archives: Biotechnology

Is there an easy way to assess the value of a biotech or pharmaceutical company based on its potential, cash, and asset position while adjusting for potential risk?

Are there any easy ways to enter an investment at a stage in which a company has passed a key FDA approval level for one of its drugs?

Biotech investors must recognize these issues. Weighing up the risk, and whether or not the company stock is over or undervalued, is a basic investment concern but one that can be hard to navigate in the Biotech industry. Various websites do provide information which makes the task easier, though.

Historical and Current Sector P/E

As reported in Forbes.com, biotech company values can achieve an extraordinary high P/E ratio when they're successful, and sentiment favors this sector. In 2015, on the most recent biotech stock 'highs', Zero Hedge reported that about 75% of biotech companies were not creating any profit despite high valuations. Perhaps this led many investors to assume the biotech industry was in a bubble. Investing in biotech isn't comparable with any other form of technology. Biotech companies acquire significant levels of venture capital to fund very long-term and extremely expensive new drugs and rely on high share price valuations to achieve this.

According to Investopedia:

Pharmaceutical stocks typically trade at a large discount to biotech stocks. The historical mean forward P/E multiple is 16x from 1976 through March 2013 for pharmaceuticals as compared to the high 20x to 30x or more for biotech.

Market Realist.com summarizes valuation factors:

A biotechnology company's (NASDAQ:IBB) value is comprised of two main factors: assets in place and growth assets. Assets in place, or drugs currently being sold in the market, are indicators of the present cash generation capacity of the biotechnology company. Growth assets involve drugs in a company's research and development (or R&D) pipeline as well as future licenses and collaborations with other pharmaceutical and biotechnology companies.

Many biotechnology companies carry substantial debt on their balance sheets. EV-to-EBITDA value can be used to determine the attractiveness of a mature biotechnology company. Low EV-to-EBITDA ratios may signal that the market is undervaluing the stock.

Since a large portion of a biotechnology company's value is derived from its R&D assets, discounted cash flow valuation (or DCF) proves to be a more effective valuation technique. However, this method is extremely sensitive to inputs related to future riskiness and returns of the company. So, wrong inputs can lead DCF in returning erroneous company values.

The problem is, of course, discounting for risk.

It can take 10 years or more to take basic experiments to a commercially viable product, and each stage requires extensive funding. There's a lot of risk involved, especially at the early stages, but investors in those companies which succeed are often generously rewarded. Weighing up risk is as crucial as buying at the right price; the two go together.

'Techinvest Daily' has a valuation suggestion. Here are some additional ideas, too, on where to source useful info, how to buy into a company which has just reached an FDA approval, reducing at least one level of risk.

FDA Approval Is A Lengthy, Costly, and Risky Business

Unlike P/E valuations (which are based on earnings, so exclude many small biotech companies) and 'DCF' (which is based on a cash flow measurement, a biotech valuation needs to account for reduced risk, as well as a product which is becoming increasingly viable as it successfully clears each of the three main hurdles needed for approval of each drug.

Assessing The Value Of The Pipeline and Third Party Resources

For example, a company has four products developing in its pipeline. We can assess a top value for each drug by multiplying its projected market share by its potential value, "assuming approval".

We can then risk adjust, the possibility of not passing regulations, by multiplying the value of each drug by the likelihood of its approval (the three hurdle assessment). This delivers a 'Risk Adjusted Value' or RAV which can be added together for the total company pipeline.

It would be difficult for investors to decide on the likelihood of approval in advance. There are websites which specialize in biotech company information like Biospace. The BioMedTracker Drug Intelligence Platform tracks company pipelines and drug catalysts, but otherwise, risk has to be assessed based on what's happened to other products trying to achieve similar results. Information is available from the FDA itself. Some sites which flag which products are waiting on approval include Biopharmcatalyst.com.

The Value of The Market Opportunity

Potential revenue numbers are usually provided by specialist biotech market intelligence companies, anticipating the potential for a company to acquire a share of a particular drug market. It doesn't account for potential profit. 30% of revenue or more can be lost to a drug distribution channel and profit influenced by costs like:

Other substantial costs can include sales and marketing (which can be significant to create national cover), as well as patent, office, and administration fees.

Risk Valuation Example

E.g. Company X

Maximum potential of $1 billion. RAV value, $500m (after adjusting for market share and the one-third level risk and likelihood of achieving that, the pipeline is worth $500m at the particular stage the products are at, plus cash, less debt).

Share value is (RAV + cash - debt/shares outstanding)

So, if company X were to have $50m in cash and $30m in debt, the calculation would look like:

$500m + $50m - $30m/50 million outstanding shares

or $520m/50 million shares means the stock is a good buy, trading under $10.20 relative to its risk.

Risk adjusted Value (RAV) = product valuation * market share * likelihood of approval

Risk Avoidance Measures

It's possible to avoid the individual company risk issues (while sacrificing some of the stock appreciation performance) by investing in one of the ETFs which track the biotech industry, like IBB. Service fees can accumulate for regular trading, though.

Armed with some specialist advise and having compared other companies developing similar products and their outcomes, an investor is able to make an improved risk judgement using the methods suggested. An investor can then decide whether buying into the stock is worth the risk involved in the pipeline. Further risk is reduced on buying a stock immediately following FDA approval of individual products, and potentially most advantageous following stage three approval.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The rest is here:
Value A Biotech Company Against Risk - Seeking Alpha

Biotechnology Separation Systems Market

Overview

The report on the Global Biotechnology Separation Systems Market 2017 gives complete view of the market across the globe. In-depth analysis comprising key market players, market forecasts, supply, demand, profit, latest market trends, and many more are provided in the report below. The future aspects impacting the global market in every possible way are also further discussed in the report.

What our report offers:

View Free Sample Report @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#RequestSample

Biotechnology Separation Systems Market: Research methodology

To Know More, Ask Our Expert @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#InquiryForBuying

Additional information provided in the report

In addition, considering that the global economy is ever-changing depending upon several factors , it is important to take a note that our report contains data that are not only conducted regarding CAGR forecasts but it also analyzes the key parameters such as yearly market growth in order to have complete information about the future of the market worldwide. It also helps in identifying the wide opportunities that will open up for the market. The other key feature included in this report is the analysis of the revenue forecasts of all the important regions and applications, which is in terms of dollars.

About Market research Store

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:

Joel John 3422 SW 15 Street, Suit #8138, Deerfield Beach, Florida 33442, USA USA Tel: +1-386-310-3803 GMT Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@marketresearchstore.com Web: http://www.marketresearchstore.com/

Read more:
Biotechnology Separation Systems Market 2017 Industry Analysis, Size and Share - World Of WallStreet

The Economic and Financial Crimes Commission, EFCC, says it has arrested Lucy Ogbadu, the Director-General of National Biotechnology Development Agency (NABDA), over alleged N23 million fraud.

The spokesperson of the commission, Wilson Uwujaren, disclosed this in a statement he issued on Thursday.

Mr. Uwujaren said Ms. Ogbadu was picked up by EFCC operatives in Port Harcourt on Wednesday, following her alleged link with the Bayelsa State Director of Bio-resources Development Centre, Josiah Habu.

Mr. Habu, according to him, is being investigated by the anti-graft agency in a case of fraudulent diversion of N75 million.

He said investigations by the EFCC revealed that Ms. Ogbadu allegedly received N23 million through a bank account belonging to the wife of Mr. Habu, Esther Habu.

The EFCC spokesperson stated that Ms. Ogbadu admitted the transaction in a voluntary statement made to the commissions investigators.

Further investigations also revealed that Mrs Habu is one of the contractors with Bio-resources Development Centre, Odi, Bayelsa State.

A total of N603 million has been traced to her in different deals involving over 20 directors of the centre across the country.

Ogbadus involvement is being investigated. She has been duly served with bail conditions while investigations continue, Mr. Uwujaren added.

Ms. Ogbadu, a professor of microbiology, was appointed NABDA director-general in November 2013.

(NAN)

More here:
Director General of Nigeria's biotechnology agency arrested over N23 million fraud - Premium Times

Press articles about Puma Biotechnology (NYSE:PBYI) has been popular fairly negative last few days, Accern reports. The analytics team pointing out the bullish and bearish news analysis by observing larger than 20 Million public financial documents, market websites and SEC sources in real-time. Accern grades analysis of public companies ranging from -1 to 1, with ranks nearest to 1 is considered more positive. Puma Biotechnology achieved a news impact rank of -0.01 on Accerns range. Accern issued stories about the biopharmaceutical company a media impact point of 66 out of 100, pointing that recent news analysis is likely to impact the share value upcoming future.

Puma Biotechnology (NYSE:PBYI) previously disclosed its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) Earnings per share for the period, reaching the Thomson Reuters average forecast of ($2.06) by $0.09. Brokerage firms predict that Puma Biotechnology to post ($8.50) earnings per share for the full year.

Puma Biotechnology (NYSE:PBYI) transacted up 4.71% throughout intraday market trading on early Wed, topping $88.85. the share had a trading volume of 872,030 Stocks. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00. The stocks market valuation is $3.28 B. Companys 50 Day SMA is $59.74 and its 200 day SMA is $42.39.

PBYI has been the topic of many Study analysis. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 target price for The corporation in a study note on Sunday, May 28th. Zacks Lowered Puma Biotechnology from a buy recommendation to a hold recommendation in a analysis note on early Wed, Jun 14th. Stifel Nicolaus reiterated a buy recommendation and fixed a $105.00 target price on stock of Puma Biotechnology in a study note on early Mon, Jun 5th. J P Morgan Chase & Co reissued an overweight recommendation and fixed a $89.00 target price on stock of Puma Biotechnology in a study note on early Tue, Jun 6th. Lastly, Royal Bank Of Canada boosted their target price on Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis note on Tue, Jun 6th. 1 investment expert has recommended the share with a sell recommendation, two have published a hold recommendation and six have published a buy recommendation to The corporation. Puma Biotechnology currently has a average recommendation of Buy and an consensus price target of $86.94.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade on early Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a transaction filed with the securities and exchange commission, which is available through the Security and Exchange Commission website. executive have unloaded 1,990,088 stocks of company shares valued $157,553,113 during the last ninety days. Executives own 22.70% of the firms stock.

Read more here:
Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis - Insider Tradings

European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the companys app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.

Seventure Partners said it ran the investment through its Health for Life Capital investment vehicle, as part of a $12m series A fundraising.

DayTwo has exclusively licensed technology from Weizmann Institute to predict how a specific diet impacts the individual blood glucose level. After the companys app is fed with HbA1c results, lifestyle factors and sequence analyses of the individual microbiome, its machine-learning predictive algorithms provide personalised nutrition recommendations on a users smart device.

Seventure Partners announced its investment was made in syndication with Johnson & Johnson as well as historical investors. DayTwo wants to use the fresh capital to commercialise its product internationally beyond Israel and develop new products tailored for other user segments. According to DayTwo, currently, the app is marketed in Israel as a wellness product that targets highly-motivated consumers, giving them insight into how to manage the food choices that are best for them. The company is currently preparing the US market launch with the same purpose.

However, the companys ultimate goal is to additionally enter a higher-price market segment for its app: as a proven medical product that prevents or slows the development of diabetes. In February, DayTwo joined forces with J&J susidiary Janssen Biotech to develop personalised microbiome analysis for diabetes nutrition. The cooperation is designed to provide clinical data that will help DayTwo to submit the product for approval from the US Food and Drug Administration (FDA) and corresponding authorities in other countries.

According to Seventure Partners CEO Isabelle de Cremoux, DayTwo rounds out our microbiome portfolio. Current investments include French Enterome SA (microbiome modulator drugs, diagnostics and companion diagnostics), LNC (drug-probiotic and nutrition microbiome-modulator products), Maat Pharma (autologous microbiome transplant), TargEDys (bacteria for regulation of appetite) and Vedanta (drug-probiotic).

Read the original post:
Diabetes: J&J and Seventure Partners launch investment - European Biotechnology

The new skin care line is expected to be launched in the third calendar quarter of 2017. CBD Biotechnology Co. Ltd. plans to use multiple sales channels to implement its sales plan including Tmall, TaoBao, the Company's official website, broadcasting platforms of internet celebrities, mobile news applications, and a multi-level direct selling system in cooperation with Shangdong Yibao Biologics Co. Ltd.

"Following the launch of OptHemp Ultra Premium Hemp Oil by CIIX's wholly owned U.S. subsidiary, ChineseHempOil.com, Inc., I am very pleased to announce the launch of CBD Biotechnology Co., Ltd. non-industrial hemp infused skin care line," says Summer Yun, CEO of CBD Biotechnology Co., Ltd. "CBD Biotechnology Co., Ltd. will be one of the first companies in China to incorporate hemp-based CBD into skin care products, which we believe will spark public interest.

"An estimated 55,700 metric tons of industrial hemp are produced around the world each year with China, Russia, and South Korea leading in production, accounting for 70 percent of the world's industrial hemp supply. Although China is one of the leading producers of industrial hemp, the benefits to the human body have not yet been widely recognized in mainland China," says Yun. "As one of the companies company to introduce a skin care line infused with hemp-based CBD to China, CIIX looks forward to educating the almost 1.4 billion people in China about the benefits of hemp-based CBD and the positive effects it can have on the largest, visible human organ - the skin!"

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A San Gabriel, CA 91776

Investor Relations: Alan Klitenic +1-214-636-2548

Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com +1-212-418-1217 Office Editor@NetworkNewsWire.com

SOURCE ChineseInvestors.com, Inc.

Go here to read the rest:
ChineseInvestors.com, Inc.'s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp ... - PR Newswire (press release)

Bengaluru: The Karnataka IT and Biotechnology department on Wednesday granted Rs 3.18 crore to fund 12 start-ups in the areas of agriculture, biotechnology, security, communications and robotics.

"The dozen start-ups have been selected for funding to innovate products and solutions as they have been part of the Idea2PoC (Proof of Concept) scheme of the IT department's Start-up Cell," said an official statement in Bengaluru.

The Idea2PoC is a part of the country's first multi-sector start-up policy, unveiled by the state government to encourage entrepreneurs with funding to commercialise their innovation.

The start-ups with seed funding are Dr. Live Software (Rs 10 lakh), EasyKrishi (Rs 15 lakh), Lightmetrics (Rs 30 lakh), PiOctave Solutions (Rs 30 lakh), Geeksynergey Technologies (Rs 30 lakh), ispAgro Robotics (Rs 20 lakh), Astrome (Rs 30 lakh), Esyasoft (Rs 20 lakh), Geotraq Safety (Rs 45 lakh), NammaNimma Cycle Foundation (Rs 10 lakh), Sirena Technologies (Rs 48 lakh) and Selfdot Technologies (Rs 30 lakh).

"Though Bengaluru is the country's IT hub, we are seeing its start-up culture spreading to other areas, including agriculture, biotechnology, security, communications, robotics and gaming rapidly. Our aim is to mentor and help them to become self-sufficient," said IT & BT Principal Secretary Gaurav Gupta on the occasion.

Kartnataka Biotechnology and Information Techology Services (KBITS) Managing Director Salma K. Fahim said the state government was also targetting start-ups in emerging technologies such as animation, artificial intelligence, big data and virtual reality.

"These technologies can solve our long-standing problems, create hundreds of jobs and help in the 'Make in India' programme of the central and state governments," added Fahim.

See more here:
Karnataka IT and Biotechnology Dept Grants Rs 3.18 cr to 12 Start-ups - News18

IShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) was lowered by investment analysts at crowd sourced stock rating company Vetr from a buy recommendation to a hold recommendation in a research note released to investors and clients on early Mon, Jun 5th. Firm has a $307.00 PT on the financial services providers shares. Vetrs target price points a possible drop of 1.25% from the firms prior close.

IShares Nasdaq Biotechnology Index Fund (IBB) transacted up 1.443% through out intraday market trading on early Mon, topping $315.375. 899,883 stocks of the shares transacted hands. Companys 50 Day SMA is $293.14 and its 200 SMA is $286.87. iShares Nasdaq Biotechnology Index Fund has a 1 year low of $240.30 has a 1 year high of $316.00.

On the other hand, Credit Suisse Group boosted iShares Nasdaq Biotechnology Index Fund from a market weight recommendation to an overweight recommendation in a study on Tue, Mar 21st. The move was based on the current stock valulation.

Most recently the business also announced a periodic dividend, expected to be paid on early Fri, Jun 30th. Investors with a record date on Early Thur, Jun 29th will be given a $0.1768 dividend. The ex-dividend date of this dividend is Tue, Jun 27th. this indicates a $0.71 dividend on a yearly basis and a payout of of 0.23%.

Quite a few investment firms and many large funds have acquired or sold some of the position in IBB. Morgan Stanley upped its stake in iShares Nasdaq Biotechnology Index Fund by 16.3% in the Q1. Morgan Stanley has an ownership of 1,774,505 stocks of the financial services providers shares valued $520,408,000 after scooping up an extra 248,914 shares through out the quarter. JPMorgan Chase boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 45.7% in the Q1. JPMorgan Chase has an ownership of 782,179 stocks of the financial services providers shares valued at $229,389,000 after scooping up an extra 245,458 shares through out the quarter. Alliancebernstein boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 40.9% in the Q1. Alliancebernstein has an ownership of 481,442 stocks of the financial services providers shares valued at $141,192,000 after scooping up an extra 139,657 shares through out the quarter. PNC Financial Services Group boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 1.0% in the Q1. PNC Financial Services Group has an ownership of 210,978 stocks of the financial services providers shares valued at $61,872,000 after scooping up an extra 2,112 shares through out the quarter. Lastly, Janney Capital Management boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 34.6% in the Q1. Janney Capital Management has an ownership of 110,807 stocks of the financial services providers shares valued at $32,496,000 after scooping up an extra 28,503 shares through out the quarter. hedge fund investors and investment firms has an ownership of 69.06% of the firms stock.

About iShares Nasdaq Biotechnology Index Fund

IShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment data that correspond generally to the price and pay out performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Continued here:
iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep - Insider Tradings

Research Firm Zacks boosted Puma Biotechnology (NYSE:PBYI) from a hold recommendation to a buy recommendation in a study note released on Early Thur, Jun 8th. Research Firm Zacks presently has $89.00 price objective on the biopharmaceutical firms shares.

Several stock researchers also recently released study analysis regarding the company. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 price objective on the company shares in a study report on Sunday, May 28th. Stifel Nicolaus reissued a buy recommendation and gave a $105.00 target price on the stock of Puma Biotechnology in a study report on early Mon, Jun 5th. J P Morgan Chase & Co reaffirmed an overweight recommendation and given a $89.00 target price on the stock of Puma Biotechnology in a study report on early Tue, Jun 6th. Royal Bank Of Canada upped their target price on the stock of Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis report on Tue, Jun 6th. Lastly, Cowen and Company boosted Puma Biotechnology from a neutral recommendation to an outperform recommendation and fixed a $91.00 price objective on the company shares in a study analysis published on early Thur, May 25th. 1 equity analyst has recommended the share with a sell recommendation, two have published a hold recommendation and six have issued a buy recommendation to The corporation. the share presently has a consensus rating of Buy and an consensus price target of $86.94.

According to Research firm Zacks, Puma Biotechnology Stocks soared quite recently following an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, The corporation is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems highly likely. An approval would be a huge rise for The corporation issued the immense commercial possible in the recipient market. However, dependence on the successful development and of a single candidate May severely hurt the firms growth prospects in case of any adverse development or regulatory setback. stocks of the company have outperformed the industry in the past 52 week.

Puma Biotechnology (PBYI) started trading at 85.95 on Early Thur. the firms valuation is $3.18 B. the company has 50 day SMA of $59.74 and a two hundred SMA of $42.39. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00.

Puma Biotechnology (NYSE:PBYI) previously issued its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) EPS for the period, reaching the Zacks average forecast of ($2.06) by $0.09. on consensus, financial stock experts expect that Puma Biotechnology to post ($8.50) EPS for the present financial year.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade dated Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a document with the securities and exchange commission, which is accessible through this link. executive have unloaded a total of 1,990,088 stocks of company shares valued $157,553,113 in the previous 90 days. corporate executives has an ownership of 22.70% of the firms stock.

Hedge funds have lately adjusted their holdings of The corporation. Bank of Montreal Can bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $195,000. Alambic Investment Management bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $201,000. Parametric Portfolio Associates bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $257,000. Perceptive Advisors bought a new stake in stocks of Puma Biotechnology in Q4 which is worth at $225,000. Lastly, Weiss Multi Strategy Advisers bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $335,000. investment firms and many large funds has an ownership of 80.98% of the firms stock.

About Puma Biotechnology

Puma Biotechnology, is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The corporation focuses on in-licensing the development and commercialization rights to over around three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

The rest is here:
Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks - Insider Tradings

Our mission: providing reliable solutions for the bioprocess market that will enable an improved quality of life

Applikon Biotechnology is a world leader in developing and supplying advanced bioreactor systems from laboratory scale to production scale. We are the only company that can take a customer from the initial screening stage up to full-scale production using the same platform. This minimizes scale-up risks and guarantees the shortest time to market for our customers new product development.

Applikon is known for bringing new technologies to the market. These new technologies offer advantages in process efficiency for research and development as well as pilot plant and production scale processes.

As a focused medium sized company we live by our motto A Step Ahead to differentiate ourselves from other suppliers. Our focus on developing bioreactor systems only, allows us to produce state-of-the-art equipment. This has resulted in a steady growth to the top position of the worldwide laboratory bioreactor market. The basis for our new product development lies in our strong cooperation with leading international universities and institutes.

As a privately owned company our focus is not on short-term shareholders value but on building a healthy company by supplying the best product offering for our customers now and in the long-term future. This is the basis of many long-term relations with our clients all over the world.

All our efforts are focused on supplying the best solution for our clients in the biotech and pharmaceutical industry. Validation and documentation is a vital part of our development procedures and this is extended throughout our whole company.

Applikon Biotechnology is unique in the mini and micro bioreactor range. No other company can offer a complete solution on this very small scale. We develop systems on a small scale that generate results that can be scaled to production scale. At the moment there are thousands of Applikon bioreactors used in the world from small scale R&D up to full scale cGMP production.

Since we started in 1974 we have shown a healthy growth and profit. R&D is done in house in our headquarters in Delft, The Netherlands. Design and engineering is done in house but real manufacturing is outsourced. Final assembling is done in-house (in our manufacturing sites in Delft and Guangzhou) as well as the final testing and documentation. We have our own sales and service organizations in the USA (Foster City, California and Dover, New Jersey), the UK (Tewkesbury) and China (Guangzhou). We have well trained local distributors for sales and service in over 30 countries.

We are continuously executing strategic plans to grow the top-line and strengthen our financial performance. New and ongoing programs are exploring new markets, developing innovative products, improving service to customers, increasing efficiency, and reducing costs.

Visit link:
Applikon Biotechnology - European Pharmaceutical Review